Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery

The KRAS mutation is present in ~20% of lung cancers and has not yet been effectively targeted for therapy. This mutation is associated with a poor prognosis in non-small-cell lung carcinomas (NSCLCs) and confers resistance to standard anticancer treatment drugs, including epidermal growth factor re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mao, Cheng-Qiong, Xiong, Meng-Hua, Liu, Yang, Shen, Song, Du, Xiao-Jiao, Yang, Xian-Zhu, Dou, Shuang, Zhang, Pei-Zhuo, Wang, Jun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2014
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015238/
https://ncbi.nlm.nih.gov/pubmed/24496383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.18
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller